Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Grants Daily Multiple Sclerosis Pill Priority Review Status

By Pharmaceutical Processing | February 22, 2010

Fingolimod, an investigational daily multiple sclerosis (MS) pill, has achieved priority review by the Food and Drug Administration (FDA). Following submission of a new drug application (NDA) in December 2009, the US regulatory body has, for the first time, granted priority review of an oral MS drug. Fingolimod has the potential to answer an unmet clinical need.

Priority review, granted to medicines with high unmet need or in areas with inadequate available treatments, means that the review time will be six months instead of ten. It is hoped fingolimod will be available in the US this year. Fingolimod was submitted for European review at the end of 2009.

“We welcome the decision granting priority review to fingolimod, which underscores the potential benefits of this medicine to patients,” said Trevor Mundel, MD., Global Head of Development at Novartis Pharma AG. “MS is a leading cause of neurological disability in young adults, particularly in women, and this medicine has the potential to offer real advances in the care of people with MS.”

The submission was based on positive data for fingolimod, which was recently published in the New England Journal of Medicine (NEJM). Data from the Phase III pivotal studies, FREEDOMS and TRANSFORMS, confirm the significant efficacy of fingolimod in reducing relapses and disability progression in patients with relapsing-remitting MS – the most common form of the disease.

Fingolimod has a well-studied safety profile, with over 5,300 patient years of exposure. The fingolimod MS study programme includes more than 4,000 patient years of exposure, with some patients in the sixth year of therapy, making it the largest Phase III clinical trial programme ever conducted in MS. This robust clinical trial programme strengthens the potential for fingolimod to be the first approved product in a new therapeutic class called S1P receptor modulators.

As stated in the NEJM, an available oral treatment option for patients with MS is highly desirable to improve convenience, diminish side effects and improve compliance. Fingolimod’s novel mode of action also means that its suppressive effect on the immune system can be reversed if treatment is stopped, allowing circulating lymphocytes to regain normal levels within weeks

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE